Ando M,Okamoto I,Yamamoto N,Takeda K,Tamura K,Seto T,Ariyoshi Y,Fukuoka M Y .2006 .Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol., 24(2) : 2549-56.
Attia M,Huet E,Gossard C,Menashi S,Tassoni MC,Martelly I .2013 .Early events of overused supraspinatus tendons involve matrix metalloproteinases and EMMPRIN/CD147 in the absence of inflammation. Am. J. Sport. Med, 41(4) : 908-17.
Banerjee P,Jana S,Chakraborty S,Swarnakar S S,Biochem S .2013 .Inflammation and MMPs in alcohol-induced liver diseases and protective action of antioxidants. , 50(5) : 377-86.
Bo MK,Bae YH,Koh J .2016 .AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR L858R/T790M, in non-small cell lung cancer cells. Invest, 34(4) : 407-15.
Eccles SA .2004 .Parallels in invasion and angiogenesis provide pivotal points for therapeutic intervention. Int. J. Dev. Biol, 48(3) : 583-98.
Rosell Felip E,R Felip E .2008 .Pemetrexed, non-small-cell lung cancer. NSCLC. Ther. Clin. Res. Man., 4(1) : 579-85.
Greig SL .2016 .. Osimertinib: First Global Approval. Drugs, 76(1) : 263-73.
Gridelli C,De MF,Di MM,Cortinovis D,Cappuzzo F,Mok T .2011 .Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Can, 71(1) : 249-257.
Ioannidis G,Souglakos J,Georgoulias V .2013 .Predicting toxicity in advanced lung cancer patients treated with platinum-based chemotherapy. Lun. Can. Man., 2(1) : 281-93.
Kumar VK,Rao JS .2012 .MMP-9 and uPAR regulated glioma cell migration. Cell Adh, 6(2) : 509-512.
Lu S,Cheng Y,Zhou CC,Wang J,Yang JCH,Zhang PH,Zhang XQ,Wang X,Orlando M,Wu YL M .2016 .Meta-analysis of first-line pemetrexed plus platinum treatment in compared to other platinumbased doublet regimens in elderly east asian patients with advanced nonsquamous non-small-cell lung cancer. Clin. Lung Can, 17(3) : e103-12.
Lynch CC,Hikosaka A,Acuff HB,Martin MD,Kawai N,Singh RK,Vargo-Gogola TC,Begtrup JL,Peterson TE,Fingleton B,Shirai T .2005 .MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. , 7(2) : 485-96.
Newby AC .2006 .Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Card. Vas. Res., 69(2) : 614-24.
Rosell R,Molina M A,Costa C,Simonetti S,GimenezCapitan A,Bertran-Alamillo J,Mayo C,Moran T,Mendez P,Cardenal F,Isla D F .2011 .Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin. Can. Res., 17(5) : 1160-68.
Scagliotti G,Hanna N,Fossella F,Sugarman K,Blatter J,Peterson P,Simms L,Shepherd FA .2009 .The differential efficacy of pemetrexed according to NSCLC histology: A review of two Phase III studies. , 14(3) : 253-63.
Wang Z,Duan J,Guo Q .2008 .A phase II clinical trial of celecoxib combined with platinum-based chemotherapy in the treatment of patients with advanced NSCLC as first-line treatment. Chin. J. Lung. Can., 11(1) : 425-30.
Wang Z,Chen R,Wang S,Zhong J,Wu M,Zhao J,Duan J,Zhuo M,An T,Wang Y,Bai H Y .2014 .Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC. , 9(1) : e110780.
Yoshizawa A,Fukuoka J,Shimizu S,Shilo K,Franks TJ,Hewitt SM,Fujii T,Cordon-Cardo C,Jen J,Travis WD .2010 .Overexpression of phospho-eIF4E is associated with survival through AKT pathway in nonsmall cell lung cancer. Clin. Can. Res., 16(1) : 240-248.
Yurdakul A,Akyurek N,Yilmaz S,Karakaya J,Ozturk C .2012 .Prognostic impact of matrix metalloproteinases (MMP-9 and MMP-2) and vascular endothelial growth factor expression in non-small cell lung cancer. Turk. J. Med. Sci., 42(1) : 281-288.
Zhang JG,Wang JJ,Zhao F,Liu Q,Jiang K,Yang GH .2010 .represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin. Chim. Acta., 411(11) : 846-852.